Identity
What is DSIP?
- Type
- Endogenous nonapeptide
- Sequence
- Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
- Amino acids
- 9
- Primary interest
- Sleep & stress regulation models
- Research family
- Neuro / sleep
- Use classification
- Research Use Only
Science Library · Delta sleep-inducing peptide
DSIP the science.
DSIP (delta sleep-inducing peptide) is a naturally occurring nonapeptide (nine amino acids) first described for its association with slow-wave (delta) sleep activity in early animal research. It has been studied as a neuromodulatory peptide in sleep and stress models, primarily in rodents, alongside a body of older and limited human research. The summary below collects what peer-reviewed research has explored.
9 aa
Nonapeptide
Endogenous
Origin
Preclinical
Evidence stage
Rodent & limited human
Model systems
How it works
Mechanism at a glance
Compound
DSIP
Action
Neuromodulatory signaling
Effect
Sleep & stress models
Studied for
Sleep regulation models
Evidence to date
In vitro
Animal
Human
Evidence to date: mainly animal models with limited, older human studies.
What it is
DSIP is a small endogenous peptide with the sequence WAGGDASGE, originally isolated from cerebral venous blood in studies of sleep regulation. It crosses the blood-brain barrier and has been treated as a research probe of central sleep and stress signaling rather than as a single, well-defined receptor ligand — its precise mechanism remains a subject of investigation.
Because of its historical link to delta-wave sleep, DSIP has been used in the laboratory to ask how a neuromodulatory peptide might influence sleep architecture, circadian patterns, and the body’s response to stressors.
Pathways under study
DSIP research spans several connected areas:
- Sleep regulation — effects on slow-wave (delta) sleep and overall sleep architecture in animal models.
- Stress & neuroendocrine response — interactions with stress-hormone signaling examined in rodent studies.
- Neuroprotection — exploratory models, including recovery-of-function paradigms after experimental injury.
What research has explored
DSIP literature is largely preclinical, concentrated in rodent models, with some older and limited human studies:
- Stroke / motor-recovery models (2021). A study in Molecules reported that DSIP was associated with recovery of motor function in rats after experimental focal stroke.
- Delivery & blood-brain-barrier research (2024). Work in Frontiers in Pharmacology examined DSIP fusion peptides in the context of crossing the blood-brain barrier.
- Historical sleep & stress studies. A body of earlier literature explored DSIP in sleep-architecture and stress-response paradigms.
These are findings in animals and limited human studies; routine human therapeutic use is not established.
Current state of the evidence
The DSIP evidence base is predominantly preclinical, with only limited and largely historical human data. No human safety, dosing, or efficacy is established here. DSIP is supplied strictly as a research material for laboratory investigation.
Compound Snapshot
At a glance
Evidence base
Research maturity
Preclinical
Rodent models
Limited human data
Maturity
Largely preclinical
Mainly rodent-model studies with limited, largely historical human research.
Translation
Not established in humans
Animal findings do not establish human safety, dosing, or benefit.
Sources & References
Peer-reviewed research and database records
Molecules / PubMed
Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke
2021 · PMID 34500605 · DOI 10.3390/molecules26175173 View SourcePubChem
Delta sleep-inducing peptide compound search
NIH PubChem lookup for molecular identity and structure records. View SourcePubMed
DSIP / delta sleep-inducing peptide literature search
NCBI PubMed index for primary papers, reviews, and PMID-linked records. View SourceFor research use only. Not for human or veterinary use. These products have not been evaluated by the FDA. Nothing on this page is medical advice or a therapeutic claim.
Catalog